+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Asia Pacific Cell Therapy Market Size, Share & Trends Analysis Report by Use-type (Clinical-use, Research-use), by Therapy Type (Autologous, Allogeneic), and Segment Forecasts, 2021-2028

  • ID: 5390508
  • Report
  • June 2021
  • Region: Asia Pacific
  • 135 Pages
  • Grand View Research

FEATURED COMPANIES

  • ANTEROGEN. CO., LTD
  • Curocell, Inc.
  • Gilead Sciences, Inc.
  • Kolon TissueGene, Inc.
  • MEDIPOST
  • Novartis AG
The Asia Pacific cell therapy market size is expected to reach USD 2.9 billion by 2028. The market is expected to expand at a CAGR of 14.9% from 2021 to 2028. Rapid advancements in regenerative medicine are anticipated to provide effective solutions for chronic conditions. A substantial number of companies in the growing markets, such as India and South Korea, are striving to capitalize on the untapped opportunities in the market, thereby driving the market.



The growth is greatly benefitted by the fund and regulatory support from government bodies and regulatory agencies. For instance, in August 2020, the government of South Korea passed an Act on the Safety and Support of Advanced Regenerative Medical Treatment and Medicine to establish a regulatory system for patient safety during quality control and clinical trials, and to strengthen the regulatory support for regenerative medicine development.

The implementation of the act is expected to enhance clinical studies and approvals of regenerative medicine in South Korea. Furthermore, CAR-T and TCR T-cell therapies have already revolutionized hematologic cancer treatment. With the onset of the COVID-19 pandemic, scientists are deciphering its potential against the novel coronavirus. The concept of using T cells against chronic viral infections, such as HIV and hepatitis B, has already been proposed.

Based on the previous research insights, Singapore-based Duke-NUS medical school’s emerging infectious diseases research program demonstrated the utility of these immunotherapies in treating patients with COVID-19 infection. Thus, an increase in research for use of cell therapies for COVID-19 treatment is expected to drive the market in Asian countries. In April 2021, a team of researchers from Japan used induced pluripotent stem cells (iPS) to find drugs that can effectively inhibit the coronavirus and other RNA viruses.

Asia Pacific Cell Therapy Market Report Highlights

  • The research-use segment accounted for the major revenue share in 2020. This can to a substantial investment in research and their clinical translation in Asian countries
  • The segment is also driven by the rapid advances in stem cell research which exhibits the potential to effectively address the unmet demand of pharmaceutical and biotech entities, as well as healthcare professionals in disease management
  • On the other hand, the clinical use segment is expected to register a significant growth rate during the forecast period owing to the success of CAR-T and other cellular therapies in recent times
  • Furthermore, the declining price of stem cell therapy products is anticipated to boost sales in this segment coupled with rising demand for effective alternatives to conventional therapies against various chronic indications
  • Based on the therapeutic area, malignancies captured the maximum revenue share in 2020
  • This can be owed to relatively more application of cellular therapies in the management of various cancer types such as acute myeloid leukemia, multiple myeloma, and non-Hodgkin lymphoma
  • The autologous therapies segment dominated the 2020 market owing to the approval of autologous CAR-T therapies, improved survival rate post transplantation procedures, and relatively higher adoption rate
  • Japan has emerged as the leading Asian market, which can be attributed to its fast growth as a hub for research on regenerative medicine
  • On the other hand, Singapore and India are anticipated to witness the fastest growth over the forecast period owing to the presence of improving financing programs to support and advance cell therapy product development in the countries

This report will be delivered within 1-3 business days.

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • ANTEROGEN. CO., LTD
  • Curocell, Inc.
  • Gilead Sciences, Inc.
  • Kolon TissueGene, Inc.
  • MEDIPOST
  • Novartis AG
Chapter 1 Methodology And Scope
1.1 Research Assumptions
1.2 Research Methodology
1.3 Information Procurement
1.4 Information or Data Analysis
1.5 Market Formulation & Validation
1.6 Regional & Country-level Market: CAGR Calculation
1.7 Market Study
1.7.1 Product mapping, By regulatory status
1.7.1.1 Products with RMAT Designations
1.7.1.2 Product study
1.7.1.2.1 MACI (Vericel Corporation)
1.7.1.2.2 LAVIV (Azficel-T) (Fibrocell Technologies)
1.7.2 Market study, by Therapeutic Area
1.7.2.1 malignancies
1.7.3 Regional analysis
1.7.3.1 Region-wise market: Base estimates
1.8 Objectives
1.8.1 Objective 1
1.8.2 Objective 2

Chapter 2 Executive Summary
2.1 Market Snapshot

Chapter 3 Cell Therapy Market Variables, Trends, And Scope
3.1 Market Trends and Outlook
3.2 Market Segmentation and Scope
3.3 Market Dynamics
3.3.1 Market driver analysis
3.3.1.1 Rise in number of clinical studies for cellular therapies in Asia Pacific
3.3.1.2 Expanding regenerative medicine landscape in Asian countries
3.3.1.3 Introduction of novel platforms and technologies
3.3.2 Market restraint analysis
3.3.2.1 Ethical concerns
3.3.2.2 Clinical issues pertaining to development & implementation of cell therapy
3.3.2.2.1 Manufacturing issues
3.3.2.2.2 Genetic instability
3.3.2.2.3 Condition of stem cell culture
3.3.2.2.4 Stem cell distribution after transplant
3.3.2.2.5 Immunological rejection
3.3.2.2.6 Challenges associated with allogeneic mode of transplantation
3.3.3 Market opportunity analysis
3.3.3.1 Approval of Kymriah and Yescarta across various Asian countries
3.3.3.2 Developments in CAR T-cell therapy for solid tumors
3.3.4 Market challenge analysis
3.3.4.1 Operational challenges associated with cell therapy development & usage
3.3.4.1.1 Volume of clinical trials for cell and gene therapy vs accessible qualified centers
3.3.4.1.2 Complex patient referral pathway
3.3.4.1.3 Patient treatment, selection, and evaluation
3.3.4.1.4 Availability of staff vs volume of cell therapy treatments
3.4 Penetration and Growth Prospect Mapping for Therapy Type, 2020
3.5 Business Environment Analysis
3.5.1 SWOT Analysis; By factor (Political & Legal, Economic and Technological)
3.5.2 Porter’s Five Forces Analysis
3.6 Regulatory Framework
3.6.1 China
3.6.1.1 Regulatory challenges & risk of selling unapproved cell therapies
3.6.2 Japan

Chapter 4 Cell Therapy Market: COVID-19 Impact analysis
4.1 Challenge’s analysis
4.1.1 Manufacturing & supply challenges
4.1.2 troubleshooting the manufacturing & supply challenges associated to COVID-19
4.1.3 Other challenges
4.2 Opportunities analysis
4.2.1 Need for development of new therapies against SARS-CoV-2
4.2.1.1 Role of T-cell based therapeutics in COVID-19 management
4.2.1.2 Role of mesenchymal cell-based therapeutics in COVID-19 management
4.2.2 Rise in demand for supply chain management solutions
4.3 Challenges in manufacturing cell therapies against COVID-19
4.4 Clinical Trial Analysis
4.5 Key Market Initiatives

Chapter 5 Asia Pacific Cell Therapy CDMOs/CMOs Landscape
5.1 Role of Cell Therapy CDMOs
5.2 Key Trends Impacting Asia Cell Therapy CDMO Market
5.2.1 Regulatory reforms
5.2.2 Expansion strategies
5.2.3 Rising investments
5.3 Manufacturing Volume Analysis
5.3.1 Wuxi Biologics
5.3.2 Samsung Biologics
5.3.3 GenScript
5.3.4 Boehringer Ingelheim
5.3.5 Seneca Biopharma, Inc.
5.3.6 Wuxi AppTech
5.4 Competitive Milieu
5.4.1 Regional network map for major players

Chapter 6 Asia Pacific Cell Therapy Market: Use Type Business Analysis
6.1 Market (Stem & non-stem cells): Use type movement analysis
6.2 Clinical Use
6.2.1 Market (stem & non-stem cells) for clinical use, 2017 - 2028 (USD Million)
6.2.2 Market (stem & non-stem cells) for clinical use, by therapeutic area
6.2.2.1 Malignancies
6.2.2.1.1 Market (stem & non-stem cells) for malignancies, 2017 - 2028 (USD Million)
6.2.2.2 Musculoskeletal disorders
6.2.2.2.1 Market (stem & non-stem cells) for musculoskeletal disorders, 2017 - 2028 (USD Million)
6.2.2.3 Autoimmune disorders
6.2.2.3.1 Market (stem & non-stem cells) for autoimmune disorders, 2017 - 2028 (USD Million)
6.2.2.4 Dermatology
6.2.2.4.1 Market (stem & non-stem cells) for dermatology, 2017 - 2028 (USD Million)
6.2.2.5 Others
6.2.2.5.1 Market (stem & non-stem cells) for other therapeutic areas, 2017 - 2028 (USD Million)
6.2.3 Market (stem & non-stem cells) for clinical use, by cell type
6.2.3.1 Stem cell therapies
6.2.3.1.1 Market, 2017 - 2028 (USD Million)
6.2.3.1.2 BM, blood, & umbilical cord-derived stem cells/mesenchymal stem cells
6.2.3.1.2.1 Asia Pacific BM, blood, & umbilical cord-derived stem cells/ mesenchymal stem Cells -derived stem cell therapies market, 2017 - 2028 (USD Million)
6.2.3.1.3 Adipose-derived stem cell therapies
6.2.3.1.3.1 Market, 2017 - 2028 (USD Million)
6.2.3.1.4 Other stem cell therapies
6.2.3.1.4.1 Market, 2017 - 2028 (USD Million)
6.2.3.2 Non-stem cell therapies
6.2.3.2.1 Market, 2017 - 2028 (USD Million)
6.3 Research Use
6.3.1 Mmarket (stem & non-stem cells) for research use, 2017 - 2028 (USD Million)

Chapter 7 Asia Pacific Cell Therapy Market: Therapy Type Business Analysis
7.1 Market (Stem & Non-stem Cells): Therapy type movement analysis
7.2 Allogeneic Therapies
7.2.1 Market (stem & non-stem cells) for allogeneic therapies, 2017 - 2028 (USD Million)
7.3 Autologous Therapies
7.3.1 Market (stem & non-stem cells) for autologous therapies, 2017 - 2028 (USD Million)

Chapter 8 Asia Pacific Cell Therapy Market: Country Business Analysis
8.1 Market (Stem & Non-stem Cells) Share by Country, 2020 & 2028
8.2 Japan
8.2.1 Market (stem & non-stem cells), by use-type, 2017 - 2028 (USD Million)
8.2.2 Market (stem & non-stem cells), by therapy type, 2017 - 2028 (USD Million)
8.3 China
8.3.1 Market (stem & non-stem cells), by use-type, 2017 - 2028 (USD Million)
8.3.2 Market (stem & non-stem cells), by therapy type, 2017 - 2028 (USD Million)
8.4 India
8.4.1 Market (stem & non-stem cells), by use-type, 2017 - 2028 (USD Million)
8.4.2 Market (stem & non-stem cells), by therapy type, 2017 - 2028 (USD Million)
8.5 Malaysia
8.5.1 Market (stem & non-stem cells), by use-type, 2017 - 2028 (USD Million)
8.5.2 Market (stem & non-stem cells), by therapy type, 2017 - 2028 (USD Million)
8.6 South Korea
8.6.1 Market (stem & non-stem cells), by use-type, 2017 - 2028 (USD Million)
8.6.2 Market (stem & non-stem cells), by therapy type, 2017 - 2028 (USD Million)
8.7 Philippines
8.7.1 Market (stem & non-stem cells), by use-type, 2017 - 2028 (USD Million)
8.7.2 Market (stem & non-stem cells), by therapy type, 2017 - 2028 (USD Million)
8.8 Australia
8.8.1 Market (stem & non-stem cells), by use-type, 2017 - 2028 (USD Million)
8.8.2 Market (stem & non-stem cells), by therapy type, 2017 - 2028 (USD Million)
8.9 Indonesia
8.9.1 Market (stem & non-stem cells), by use-type, 2017 - 2028 (USD Million)
8.9.2 Market (stem & non-stem cells), by therapy type, 2017 - 2028 (USD Million)
8.10 Singapore
8.10.1 Market (stem & non-stem cells), by use type, 2017 - 2028 (USD Million)
8.10.2 Market (stem & non-stem cells), by therapy type, 2017 - 2028 (USD Million)

Chapter 9 Asia Pacific Cell Therapy Market: Competitive Landscape
9.1 Strategy Framework
9.2 Company Profiles
9.2.1 Kolon TissueGene, Inc.
9.2.1.1 Company overview
9.2.1.2 Financial Performance
9.2.1.3 Product benchmarking
9.2.1.4 Strategic initiatives
9.2.2 JCR Pharmaceuticals Co., Ltd.
9.2.2.1 Company overview
9.2.2.2 Financial Performance
9.2.2.3 Product benchmarking
9.2.2.4 Strategic initiatives
9.2.3 MEDIPOST
9.2.3.1 Company overview
9.2.3.2 Financial Performance
9.2.3.3 Product benchmarking
9.2.3.4 Strategic initiatives
9.2.4 PHARMICELL Co., Ltd.
9.2.4.1 Company overview
9.2.4.2 Financial Performance
9.2.4.3 Product benchmarking
9.2.4.4 Strategic initiatives
9.2.5 ANTEROGEN. CO., LTD
9.2.5.1 Company overview
9.2.5.2 Financial Performance
9.2.5.3 Product benchmarking
9.2.6 Bristol-Myers Squibb Company
9.2.6.1 Company overview
9.2.6.1.1 Celgene Corporation
9.2.6.2 Financial performance (Bristol-Myers Squibb)
9.2.6.2.1 Financial performance (CelgeneCorporation)
9.2.6.3 Product benchmarking
9.2.6.4 Strategic initiatives
9.2.7 Novartis AG
9.2.7.1 Company overview
9.2.7.2 Financial Performance
9.2.7.3 Product benchmarking
9.2.7.4 Strategic initiatives
9.2.8 Gilead Sciences, Inc.
9.2.8.1 Company overview
9.2.8.1.1 DAIICHI SANKYO COMPANY, LIMITED
9.2.8.2 Financial Performance
9.2.8.2.1 Financial Performance: Daiichi Sankyo
9.2.8.3 Product benchmarking
9.2.8.4 Strategic initiatives
9.2.9 Curocell, Inc.
9.2.9.1 Company overview
9.2.9.2 Product benchmarking
9.2.9.3 Strategic initiatives
9.2.10 JW Therapeutics (Shanghai) Co., Ltd.
9.2.10.1 Company overview
9.2.10.2 Product benchmarking
9.2.10.3 Strategic initiatives
9.2.11 STEMPEUTICS RESEARCH PVT LTD
9.2.11.1 Company overview
9.2.11.2 Product benchmarking
9.2.11.3 Strategic initiatives

List of Tables
Table 1 Some approved non-CAR-T cell therapies for clinical-use
Table 2 Approved CAR-T cell therapies
Table 3 Products with RMAT Designations by the U.S. FDA
Table 4 Examples of FDA-approved regenerative medicines
Table 5 CAR T-cell resources and potential disruptions during a pandemic
Table 6 Ongoing regenerative medicine clinical trials to treat COVID-19 & related complications, as of April 14, 2020
Table 7 Registered CAR T trials for solid tumors in Singapore
Table 8 Japan cell therapy market (stem & non-stem cells) estimates & forecasts, by use-type, 2016 - 2027 (USD Million)
Table 9 Japan cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by therapeutic area, 2016 - 2027 (USD Million)
Table 10 Japan cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
Table 11 Japan stem cell therapies market for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
Table 12 Japan cell therapy market (stem & non-stem cells) estimates & forecasts, by therapy type, 2016 - 2027 (USD Million)
Table 13 China cell therapy market (stem & non-stem cells) estimates & forecasts, by use-type, 2016 - 2027 (USD Million)
Table 14 China cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by therapeutic area, 2016 - 2027 (USD Million)
Table 15 China cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
Table 16 China stem cell therapies market for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
Table 17 China cell therapy market (stem & non-stem cells) estimates & forecasts, by therapy type, 2016 - 2027 (USD Million)
Table 18 India cell therapy market (stem & non-stem cells) estimates & forecasts, by use-type, 2016 - 2027 (USD Million)
Table 19 India cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by therapeutic area, 2016 - 2027 (USD Million)
Table 20 India cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
Table 21 India stem cell therapies market for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
Table 22 India cell therapy market (stem & non-stem cells) estimates & forecasts, by therapy type, 2016 - 2027 (USD Million)
Table 23 Malaysia cell therapy market (stem & non-stem cells) estimates & forecasts, by use-type, 2016 - 2027 (USD Million)
Table 24 Malaysia cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by therapeutic area, 2016 - 2027 (USD Million)
Table 25 Malaysia cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
Table 26 Malaysia stem cell therapies market for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
Table 27 Malaysia cell therapy market (stem & non-stem cells) estimates & forecasts, by therapy type, 2016 - 2027 (USD Million)
Table 28 South Korea cell therapy market (stem & non-stem cells) estimates & forecasts, by use-type, 2016 - 2027 (USD Million)
Table 29 South Korea cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by therapeutic area, 2016 - 2027 (USD Million)
Table 30 South Korea cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
Table 31 South Korea stem cell therapies market for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
Table 32 South Korea cell therapy market (stem & non-stem cells) estimates & forecasts, by therapy type, 2016 - 2027 (USD Million)
Table 33 Philippines cell therapy market (stem & non-stem cells) estimates & forecasts, by use-type, 2016 - 2027 (USD Million)
Table 34 Philippines cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by therapeutic area, 2016 - 2027 (USD Million)
Table 35 Philippines cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
Table 36 Philippines stem cell therapies market for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
Table 37 Philippines cell therapy market (stem & non-stem cells) estimates & forecasts, by therapy type, 2016 - 2027 (USD Million)
Table 38 Australia cell therapy market (stem & non-stem cells) estimates & forecasts, by use-type, 2016 - 2027 (USD Million)
Table 39 Australia cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by therapeutic area, 2016 - 2027 (USD Million)
Table 40 Australia cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
Table 41 Australia stem cell therapies market for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
Table 42 Australia cell therapy market (stem & non-stem cells) estimates & forecasts, by therapy type, 2016 - 2027 (USD Million)
Table 43 Indonesia cell therapy market (stem & non-stem cells) estimates & forecasts, by use-type, 2016 - 2027 (USD Million)
Table 44 Indonesia cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by therapeutic area, 2016 - 2027 (USD Million)
Table 45 Indonesia cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
Table 46 Indonesia stem cell therapies market for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
Table 47 Indonesia cell therapy market (stem & non-stem cells) estimates & forecasts, by therapy type, 2016 - 2027 (USD Million)
Table 48 Singapore cell therapy market (stem & non-stem cells) estimates & forecasts, by use-type, 2016 - 2027 (USD Million)
Table 49 Singapore cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by therapeutic area, 2016 - 2027 (USD Million)
Table 50 Singapore cell therapy market (stem & non-stem cells) for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
Table 51 Singapore stem cell therapies market for clinical-use estimates & forecasts, by cell-type, 2016 - 2027 (USD Million)
Table 52 Singapore cell therapy market (stem & non-stem cells) estimates & forecasts, by therapy type, 2016 - 2027 (USD Million)

List of Figures
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modelling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Initiatives by Vericel Corporation to sustain market and boost revenue through its ATMPs
Fig. 9 Number of active therapies
Fig. 10 Top targets of cell therapies for hematological malignancies, by CAR-T cell therapy type
Fig. 11 Top targets of cell therapies for solid tumors, by CAR-T cell therapy type
Fig. 12 Factors considered for regional market share analysis
Fig. 13 Market summary, 2020 (USD Million)
Fig. 14 Market trends & outlook
Fig. 15 Market segmentation and scope
Fig. 16 Market driver relevance analysis (Current & future impact)
Fig. 17 Clinical trials for cell therapy in East Asia, as of May 2021
Fig. 18 Clinical trials for cell therapy in North Asia, as of May 2021
Fig. 19 Clinical trials for cell therapy in Pacific, as of May 2021
Fig. 20 Clinical trials for cell therapy in South Asia, as of May 2021
Fig. 21 Clinical trials for cell therapy in Southeast Asia, as of May 2021
Fig. 22 Clinical trials for cell therapy in Southeast Asia
Fig. 23 Market restraint relevance analysis (Current & future impact)
Fig. 24 Clinical trials for the use of CAR T cell therapy in solid tumors: Comparison of Asian countries with rest of the world
Fig. 25 Penetration and growth prospect mapping for therapy type, 2020
Fig. 26 SWOT Analysis, By Factor (Political & legal Economic and technological)
Fig. 27 Porter’s Five Forces Analysis
Fig. 28 Troubleshooting the challenges associated with COVID-19: Cell therapy development programs
Fig. 29 Troubleshooting the challenges associated with COVID-19: Cell therapy manufacturing & delivery
Fig. 30 Role of cell-based therapeutics in COVID-19 management
Fig. 31 Asia Pacific cell therapy market (stem cells & non-stem cells): Use type outlook key takeaways
Fig. 32 Asia Pacific cell therapy market (stem & non-stem cells): Use type movement analysis
Fig. 33 Asia Pacific cell therapy market (stem & non-stem cells) for clinical use, 2017 - 2028 (USD Million)
Fig. 34 Asia Pacific cell therapy market (stem & non-stem cells) for malignancies market, 2017 - 2028 (USD Million)
Fig. 35 Asia Pacific cell therapy market (stem & non-stem cells) for musculoskeletal disorders, 2017 - 2028 (USD Million)
Fig. 36 Asia Pacific cell therapy market (stem & non-stem cells) for autoimmune disorders, 2017 - 2028 (USD Million)
Fig. 37 Asia Pacific cell therapy market (stem & non-stem cells) for dermatology, 2017 - 2028 (USD Million)
Fig. 38 Asia Pacific cell therapy market (stem & non-stem cells) for other therapeutic areas, 2017 - 2028 (USD Million)
Fig. 39 Asia Pacific stem cell therapies market, 2017 - 2028 (USD Million)
Fig. 40 Asia Pacific BM, blood, & umbilical cord-derived stem cells/mesenchymal stem cells -derived stem cell therapies market, 2017 - 2028 (USD Million)
Fig. 41 Asia Pacific adipose-derived stem cell therapies market, 2017 - 2028 (USD Million)
Fig. 42 Asia Pacific other stem cell therapies market, 2017 - 2028 (USD Million)
Fig. 43 Asia Pacific non-stem cell therapies market, 2017 - 2028 (USD Million)
Fig. 44 Asia Pacific cell therapy market (stem & non-stem cells) for research use, 2017 - 2028 (USD Million)
Fig. 45 Asia Pacific cell therapy market (stem cells & non-stem cells): Therapy type outlook key takeaways
Fig. 46 Asia Pacific cell therapy market (stem & non-stem cells): Therapy type movement analysis
Fig. 47 Asia Pacific cell therapy market (stem & non-stem cells) for allogeneic therapies, 2017 - 2028 (USD Million)
Fig. 48 Asia Pacific cell therapy market (stem & non-stem cells) for autologous therapies, 2017 - 2028 (USD Million)
Fig. 49 Asia Pacific cell therapy market (stem & non-stem cells) regional outlook, 2020 & 2028
Fig. 50 Japan cell therapy market (stem & non-stem cells), 2017 - 2028 (USD Million)
Fig. 51 China cell therapy market (stem & non-stem cells), 2017 - 2028 (USD Million)
Fig. 52 India cell therapy market (stem & non-stem cells), 2017 - 2028 (USD Million)
Fig. 53 Malaysia cell therapy market (stem & non-stem cells), 2017 - 2028 (USD Million)
Fig. 54 South Korea cell therapy market (stem & non-stem cells), 2017 - 2028 (USD Million)
Fig. 55 Philippines cell therapy market (stem & non-stem cells), 2017 - 2028 (USD Million)
Fig. 56 Australia cell therapy market (stem & non-stem cells), 2017 - 2028 (USD Million)
Fig. 57 Indonesia cell therapy market (stem & non-stem cells), 2017 - 2028 (USD Million)
Fig. 58 Capabilities being developed in Singapore for cell therapy commercialization
Fig. 59 Singapore cell therapy market (stem & non-stem cells), 2017 - 2028 (USD Million)
Fig. 60 Strategy framework
Note: Product cover images may vary from those shown
  • Kolon TissueGene, Inc.
  • JCR Pharmaceuticals Co., Ltd.
  • MEDIPOST
  • PHARMICELL Co., Ltd.
  • ANTEROGEN. CO., LTD
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Gilead Sciences, Inc.
  • Curocell, Inc.
  • JW Therapeutics (Shanghai) Co., Ltd.
  • STEMPEUTICS RESEARCH PVT LTD
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll